Evidence-of-SARS-CoV2-in-heart-cells

Evidence of SARS-CoV2 in heart cells

While SARS-CoV2 has been previously reported to exist in lung tissue in a 78-year-old patient who died of unexpected cardiac arrest when ready for discharge after COVID-19 hospitalisation, recently the first evidence of SARS-CoV2 infection in heart muscle cells has been reported in a case from Brazil and which is supported by evidence from other reports.

triple-combination-effective-for-hospital-and-ventilator-acquired-pneumonia

Triple combination effective for hospital- and ventilator-acquired pneumonia

Pneumonia is the second leading cause of death in Hong Kong as of 2019, with annually increasing death rates.

risk-of-thrombosis-with-sars-cov-2-infection

Risk of thrombosis with SARS-CoV-2 infection

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2/2019-nCoV) in late 2019 has led to a global pandemic.

no-difference-in-kidney-transplantation-outcomes-for-HIV-positive-recipients-regardless-of-donor-HIV-status

No difference in kidney transplantation outcomes for HIV-positive recipients regardless of donor HIV status

Human immunodeficiency virus (HIV) has been transformed into a chronic disease to the successful introduction of antiretroviral therapy (ART), and people living with HIV (PWH) now experience morbidity from other chronic conditions, such as kidney, liver, and heart disease.

residual-risk-of-hepatocellular-carcinoma-in-older-hepatitis-c-patients-even-after-viral-clearance

Residual risk of hepatocellular carcinoma in older Hepatitis C patients even after viral clearance

Infection with the hepatitis C virus (HCV) can lead to chronic hepatitis C infection (CHC) and liver complications such as fibrosis, hepatocellular carcinoma (HCC), cirrhosis, and end-stage liver disease.

potential-protective-effects-of-the-influenza-vaccine-on-cardiovascular-outcomes-in-high-risk-populations

Potential protective effects of the influenza vaccine on cardiovascular outcomes in high-risk populations

Influenza A and B viruses are the cause of 3 to 5 million infection, and 250,000 to 500,00 deaths each year worldwide. Particular groups of the population are at higher risk of infection, including the elderly, immunocompromised, and infants.

updated-human-papillomavirus-vaccination-and-testing-recommendations-from-the-american-cancer-society

Updated human papillomavirus vaccination and testing recommendations from the American Cancer Society

Human papillomavirus (HPV) is one of the most common causes of sexually transmitted disease worldwide. HPV is associated with a variety of clinical conditions that can range from cutaneous warts to cervical or anal cancer. Cervical cancer is the third most common cancer in women in the United States, and may constitute up to 25% of all female cancers in developing countries.

interim-results-of-a-Phase-2b-3-trial-investigating-a-long-acting-injectable-of-cabotegravir-for-pre-exposure-prophylaxis-of-HIV

Interim results of a Phase 2b/3 trial investigating a long-acting injectable of cabotegravir for pre-exposure prophylaxis of HIV

There is no excerpt because this is a protected post.

comparison-of-the-metabolic-changes-from-the-tango-trial-a-post-hoc-analysis

Comparison of the metabolic changes from the TANGO trial: a post-hoc analysis

There is no excerpt because this is a protected post.

Carboplatin plus paclitaxel to be the new standard of care for anal cancer

Carboplatin plus paclitaxel to be the new standard of care for anal cancer

The incidence of anal cancer has been increasing over the past decade, but currently still constitutes 0.5% of all cancer diagnoses in the United States. When the cancer has metastasised, prognosis remains poor, with relative 5-year survival rates of approximately 30%. The current standard of care for metastatic anal cancer is cisplatin-based chemotherapy combined with 5-fluorouracil (5-FU). However, no randomised clinical trial investigating the optimal chemotherapy regimen for this disease has been conducted. The InterAAct trial was launched to investigate cisplatin plus FU against carboplatin plus paclitaxel in advanced anal cancers, and full results were recently published in the Journal of Clinical Oncology.

Dr Sridhar Siddharth - Clinical characteristics of patients with 2019-nCoV pneumonia COVID-19 2019-nCoV WuhanOutbreak Pneumonia

Updated: Clinical characteristics of patients with COVID-19

Dr Siddharth analysed the clinical characteristics of 1,689 #COVID19 patients from 21 publications, and the demographics of 2,198 2019nCoV patients.

Dr Siddharth Sridhar - 2019-nCoV COVID-19 in Hong Kong - the end of the beginning

COVID-19 in Hong Kong: the end of the beginning?

Watching the daily increase in Covid-19 cases in Hong Kong is scary. However, a more useful analysis is the ‘epidemic curve’, which looks at the date of symptom onset of cases rather than the date of case detection.

Dr Siddharth Sridhar - 2019-nCoV COVID-19 - How do People get Covid-19 in Hong Kong 在本港,人們如何感染Covid-19

How do people get COVID-19 in Hong Kong

Dr Siddharth Sridhar, Specialist in Clinical Microbiology & Infection, looked at the main settings of Covid-19 transmission in Hong Kong (as of 20/2/2020)

Dr Siddharth Sridhar - 2019-nCoV - Summary of the situation in HK 2019-nCoV在本港的概況 COVID-19 2019-nCoV WuhanOutbreak Pneumonia

2019-nCoV – Summary of the situation in HK as of Feb 6, 2020

Dr Siddharth Sridhar provides a brief overview on the infections with 2019-nCoV in Hong Kong as of Feb 6, 2020. Are they imported cases, local transmissions? And if locally transmitted how closely are the patients related?

Dr Sridhar Siddharth - How infectious is novel coronavirus 2019 nCoV 新型冠狀病毒 2019-nCoV 的傳染性有多高 COVID-19 2019-nCoV WuhanOutbreak Pneumonia

How infectious is novel coronavirus (2019-nCoV)

Dr Siddharth Sridhar describes the basic reproduction number – a measure of how ‘infectious’ a pathogen is and how likely it is to spread through a community – for 2019-nCoV, and compares this with the early phases of the SARS and measles outbreaks.

Dr Siddharth Sridhar - How stable are coronaviruses in the environment? 2019-nCoV 冠狀病毒在環境中的穩定性 COVID-19 2019-nCoV WuhanOutbreak Pneumonia

2019-nCoV: how stable are coronaviruses in the environment?

Dr Siddharth Sridhar, looked at how stable coronaviruses are on a variety of environmental surfaces, and provides recommendations to prevent infection with 2019-nCoV.

Dr Sridhar Siddharth - Who gets severe novel coronavirus (2019-nCoV) infection COVID-19 2019-nCoV WuhanOutbreak Pneumonia

Who gets severe novel coronavirus (2019-nCoV) infection?

Here, I examined the data of 28 patients from 5 publications who had severe pneumonia due to 2019-nCoV requiring ICU admission and/or resulting in death.